Combined ketotifen + metformin therapy

Combined ketotifen + metformin therapy is a pharmacological strategy involving the co-administration of the mast cell stabilizer/H1-antihistamine ketotifen and the biguanide anti-diabetic metformin. This combination is not a single molecular target but a therapeutic regimen primarily investigated for its potential to mitigate weight gain and metabolic dysfunction associated with atypical antipsychotic medications, such as olanzapine (Morrison et al., 2016). Ketotifen targets the histamine H1 receptor and stabilizes mast cells, which may influence appetite and inflammatory pathways (PubChem CID 3827). Metformin activates AMP-activated protein kinase (AMPK) to enhance insulin sensitivity and suppress hepatic gluconeogenesis (StatPearls, 2023). By addressing both the histaminergic and metabolic pathways, this combination aims to provide a synergistic effect in managing drug-induced obesity and insulin resistance. Clinical interest in this pairing stems from the need to improve the metabolic safety profile of psychiatric treatments. Research suggests that while metformin addresses insulin-related weight gain, ketotifen may counteract the H1-mediated appetite stimulation common in antipsychotic use. This dual approach represents a multi-target strategy to combat complex metabolic disorders.

Other names

Ketotifen and metformin combinationMetformin/Ketotifen co-administrationKetotifen-metformin therapy

Ketotifen acts as a selective H1-receptor antagonist and mast cell stabilizer to mitigate appetite stimulation and inflammation, while metformin activates AMPK to improve insulin sensitivity and reduce hepatic glucose production (PubChem CID 3827; StatPearls, 2023; Morrison et al., 2016).